Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Stock Is Sinking Today

By Keith Speights - May 31, 2019 at 11:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small biotech continued to feel the impact of a decision by its big partner.

What happened

Shares of Inovio Pharmaceuticals (INO 9.25%) were sinking 14.1% lower as of 11:08 a.m. EDT on Friday. This continued a slide that began on Wednesday after the clinical-stage biotech revealed in a regulatory filing that its partner, AstraZeneca (AZN -0.18%), is scaling back its collaboration on several clinical programs.

So what

It's not surprising that Inovio's share price would fall on news of AstraZeneca's decision. The small biotech doesn't have any products on the market to generate revenue. Most of its revenue in the first quarter came from a milestone payment received from AstraZeneca.

Scientist looking through a microscope

Image source: Getty Images.

However, AstraZeneca isn't pulling out of the most important program included in its collaboration agreement with Inovio. The two companies continue to work together in developing MEDI0457. AstraZeneca is evaluating the experimental drug in combination with its immunotherapy Imfinzi in several phase 2 clinical studies. Inovio remains eligible to potentially receive milestone payments related to the development and commercialization of MEDI0457.

Also, AstraZeneca's scaling back on its collaboration with Inovio has no impact on the biotech's lead candidate, VGX-3100. Inovio CEO Joseph Kim expressed confidence, in his remarks in the company's Q1 conference call, that Inovio remained on track to file for approval of VGX-3100 in 2021 if all goes well with its pivotal clinical studies of the immunotherapy.

Now what

The next steps for Inovio are no different than they were before the revelation about AstraZeneca's decision. Inovio plans to complete enrollment for its Reveal 1 phase 3 study of VGX-3100. It also expects to announce interim data from a couple of phase 2 studies of the drug later this year.

AstraZeneca isn't Inovio's only big partner. Inovio hopes to report interim results from a phase 1/2 study of INO-5401 in combination with Regeneron's (REGN 0.72%) Libtayo by late 2019. It also teamed up with Roche (RHHBY 0.72%) to evaluate INO-5401 in combination with Tecentriq.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.89 (9.25%) $0.16
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$65.95 (-0.18%) $0.12
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$595.40 (0.72%) $4.27
Roche Holding AG Stock Quote
Roche Holding AG
$42.01 (0.72%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.